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 Chapter 8 
 Orofacial Stem Cells for Cell-Based Therapies 
of Local and Systemic Diseases 
 Munira  Xaymardan 
 Abstract  Orofacial region and dental tissues harbour a wide range of stem/pro-
genitor cells including mesenchymal stem cells and tissue-specifi c progenitors such 
as muscle satellite cells. The stem cells of the orofacial areas are readily available, 
highly proliferative and possess multi-differentiation abilities. These cells not only 
provide therapeutic and tissue engineering cell source for the defects of orofacial 
area and dental tissues but also provide additional cell source for the diseases of 
other organs. Understanding their differentiation pathways and mechanisms will be 
imperative in developing the most appropriate approaches for stem cell-based tissue 
engineering and therapeutic strategies. 
 Keywords  Orofacial •  Stem cells •  Therapy 
8.1  Overview 
8.1.1  Need for Stem/Progenitor Cell-Based Therapy 
 Stem cells are defi ned as the cells that have two important abilities: (1) self-renewal 
and (2) differentiation. They have remarkable potential to develop into many differ-
ent cell types in the body during early life and growth [ 1 ]. In adults, they serve as a 
cell source for continuous repair system, dividing essentially without limit to replen-
ish other cells as long as the person or animal is still alive, as best exampled with the 
haematopoietic system, bone marrow (BM) stem cells providing blood cells 
throughout a person’s life. Other adult organs are less regenerative in comparison; 
still, minor wears and tears are constantly repaired with stem cells by providing 
broader matrix turnover and cellular replenishment or by exerting more specialized 
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function, such as differentiating into muscle cells, neurons, or, in the dental context, 
odontoblasts. 
 However, in adult mammalians, this reparative ability seems to be limited to 
minor injuries. In catastrophic events such as myocardial infarction (MI), spinal 
cord injury (SCI) or autoimmune and degenerative diseases, the endogenous stem 
cells do not seem to have the capacity to provide suffi cient support for the parenchy-
mal tissue regeneration. The lost tissue is often replaced by fi brous scar, compro-
mising the integrity and function of the damaged organs. Therefore, developing 
approaches that can either activate the endogenous stem cells  in vivo or expand 
them  in vitro for transplantation still hold major research interest in the regenerative 
medicine. 
 Stem and progenitor cells exert their therapeutic abilities mainly through two 
mechanisms:
 1.  Functional cellular replacement of the damaged organs, for example, replace-
ment of the neurons in SCI or replacement of the cardiomyocytes after MI. This 
aspect is the most desirable property of the stem cell therapeutics but currently is 
also diffi cult to achieve with adult stem cell sources. Embryonic stem (ES) cells 
and the induced pluripotent promise the pluripotency that can be used to differ-
entiate various cell types for transplantation, however with caveats including 
uncontrolled cell proliferations and teratogenicity limiting the clinical use of 
these cells. 
 2.  Modulation of the repair processes by providing extracellular matrix remodel-
ling, paracrine trophic factors and immune modulation. More often than not, and 
in the mesenchymal stem cell (MSC) therapies in particular, the trophic effects 
seem to play a major role in the improvement of the organ function by modulat-
ing vascular supply and maintenance of tissue architectures rather than providing 
engraftment of the parenchymal cell types. The immunomodulatory effects of 
the MSCs have been exploited to treat various diseases including cardiac injuries 
and autoimmune diseases, with cells isolated and investigated from virtually all 
organs and tissues in the body. 
 Studies of the orofacial stem cells have been relatively newer events. Majority of 
the orofacial stem cell studies have been focused on the MSC cell types of the dental 
pulp, periodontal ligaments, facial BM, submucosal stromal and tongue. In the 
meantime, studies include generation of the parenchymal cell types of salivary 
glands, and recent speculation of the possible use of the tongue myogenic progeni-
tors for cardiac repair also hold intriguing perspectives for future exploration of the 
stem cells in the orofacial region. 
 Orofacial region provides advantages over other cell sources:
 1.  Easy accessibility: Cells can be obtained from extracted third molars (pulp and 
periodontal cell sources), exfoliated deciduous teeth, oral mucosa biopsies and 




 2.  Higher potency: For example, MSCs isolated from the dental sources may pos-
sess high potencies compared to BM source as discussed below. 
 3.  Complexity: Multi-lineage derivation of the orofacial tissues that contain all 
three germ layers of embryonic origins (endoderm, ectoderm and mesoderm, as 
discussed below) that may provide expanded versatility for stem cell therapies. 
 In this chapter, we discuss the developmental cell sources of the orofacial areas 
focusing on the discussion of the MSCs derived from orofacial region and their util-
ity in the local and systemic diseases, as well as the potential promise of the orofa-
cial muscle progenitor usage for cardiac regenerations. 
8.1.2  Cell Sources During Orofacial Development 
 During vertebrate development, including humans, the oral and facial region devel-
ops very early in the embryos following formation of the cardiac tube and folding 
of the neural tube, approximately at the end of week 3 of prenatal life. The earliest 
orofacial progenitors originate posteriorly to the heart fi eld and contain vascular 
(aortic arch) and muscular progenitors, which are joined by the neural crest mesen-
chymal (also known as ectomesenchyme) progenitor migration as the neural tube 
closes [ 2 ]. Expansion of these two populations facilitates the formation of the fi rst 
and second pharyngeal arches that provide initial myogenic progenitors for orofa-
cial musculatures, including masticatory, facial expressions and tongue [ 3 ,  4 ], and 
the multi-fated neural crest progenitors for formation of facial cartilage, fl at bones, 
teeth and tooth support tissues such as periodontal ligaments [ 5 ]. Recent studies 
indicate that, albeit to a limited extent, adult tissues may retain some of these stem/
progenitor cells at various stages of the development, become dormant and, when 
activated, are able to achieve minor repairs of the tissues during injury. Indeed, stud-
ies have shown the MSCs isolated from the orofacial area are neural crest in origin 
[ 6 ] and may have different differentiation potential compared to the MSCs isolated 
from other tissues such as the BM and heart which are thought to have been derived 
from the mesodermal origin [ 7 ]. 
 At the later stages of the embryonic development, the mesodermal muscle pro-
genitors (paraxial/occipital) and mesenchymal stromal cells aid the expansion of the 
muscle cell pools and the connective tissue (including bone) maturations. However, 
these cell sources provoke less interest from orofacial stem cell research point of 
view as the clonogenic stem cells isolated from this region seem to be more neural 
crest in origin [ 8 ]. 
 The pharyngeal arches that give rise to orofacial tissues are internally lined by 
the endodermal epithelium and externally covered by the ectodermal epithelium; 
both form the oral mucosa lining as well as give rise to salivary glands [ 9 ]. Isolation 
of the myoepithelial progenitors from the salivary glands has shown to generate 
organoids in vitro and is able to engraft in the irradiated mice to form functional 
salivary glands [ 10 ]. 
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8.2  Mesenchymal Stem Cell-Derived Oral Tissues 
8.2.1  Markers and Sources of Orofacial MSCs 
 Majority of the orofacial stem cell research involves isolation of the so-called MSC 
population from various tissues. MSCs are fi rst isolated by Friedenstain from BM 
and generally described as a group of plastic adherent cells that assume a spindle- 
shaped morphology and form so-called colony-forming unit fi broblasts (CFU-F), 
which can differentiate into connective tissue cells (adipocytes, osteocytes and 
chrondrocytes) in vitro [ 11 ]. In the orofacial region, the MSCs are isolated from 
adult human dental pulp, pulp of the exfoliated deciduous teeth, periodontal liga-
ments, apical follicles, mandibular BM and oral mucosal connective tissues that can 
be transplanted to various organs. 
 Similar to the MSCs derived from other tissues, orofacial MSCs do not display 
any tissue-specifi c markers  in vivo . Some of the markers of  in vitro derivatives of 
dental pulp stem cells (DPSCs) and periodontal ligament stem cells (PDLCs) 
include stromal markers such as CD90, CD44, CD13, CD19 and CD79 and pericyte 
markers such as CD146. In mouse, the MSCs are marked within a broader stromal 
population of the stem cell antigen 1 (Sca-1)-positive cohorts. In humans, Stro-1 
and CD34 were described as MSC makers that can be used to isolate the  in vitro 
 CFU-F forming cells, albeit all these markers are expressed by other cell types and 
highly unspecifi c. Recently, platelet-derived growth factor receptor alpha (PDGFRa) 
has been described as a possible  in vivo  marker for the enrichment of MSC CFU-F 
forming ability  in vitro and engraftment  in vivo [ 12 ,  13 ]. Studies have shown that 
the PDGFRa expresses broadly in the neural crest cells, [ 14 ] and in the dental 
organs, clonogenic MSCs can be isolated from the dental pulp tissue using this 
marker [ 8 ]. However, no comprehensive enrichment studies have been conducted 
using PDGFRa . Similar to other MSCs, these cells generally lack haematopoietic 
cell markers such as CD45 and CD31 [ 1 ,  15 ]. 
 Orofacial MSCs cells originate from the embryonic neural crest, generally 
described as possessing higher differentiation potencies than the MSCs isolated 
from other sites [ 16 ]. For example, MSCs isolated from the mandibular bone can 
engraft and regenerate tibial defect but the reverse is not possible. Dental pulp 
MSCs express embryonic markers that are not expressed in the MSCs isolated from 
other tissues as detailed below. This is partially due to a cordial form of Hox gene 
expression in these cells compared to the mesoderm-derived MSCs [ 17 ]. 
 The presence of adult MSC populations within orofacial tissue, and their ability 
to adopt tissue-specifi c phenotypes, given the appropriate differentiation conditions, 
has led many investigators to suggest that the primary role of MSCs is to serve as 
cell replacement during the natural course of tissue turnover and homeostasis [ 18 ]. 
In addition, MSCs may serve important therapeutic roles because they appear to 
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escape immune recognition and exert anti-infl ammatory and immunomodulatory 
effects via the suppression of T, B, natural killer and antigen-presenting cells, both 
 in vitro and  in vivo . The immunomodulatory properties of these cells, and the ability 
to isolate and expand them  in vitro  without loss of their phenotypic or multi-lineage 
potential, have generated great interest in using MSCs as a therapeutic modality for 
immune-mediated diseases and tissue repair [ 19 – 21 ]. 
8.2.2  Mesenchymal Stem Cells of Dental Pulp Stem Cells 
(DPSCs) 
 Dental pulp tissue is derived from the embryonic dental papilla, which originates 
from neural crest mesenchymal cells during the morphogenesis of the fi rst pharyn-
geal arches. DPSCs are presumably inherent descendants of this lineage that occupy 
a perivascular niche of the dental pulp and possess MSC-like properties [ 15 ]. Dental 
pulp tissue is isolated from coronal pulp of the routinely extracted human teeth or 
exfoliated deciduous teeth, therefore a non-invasive process. DPSCs have shown to 
generate bone when they are implanted in mice [ 22 ]; deciduous teeth MSCs were 
found to be able to induce bone formation, generate dentin and survive in mouse 
brain along with expression of neural markers that appear to be different from previ-
ously identifi ed stem cells such as from BM [ 23 ]. 
 In culture, DPSCs have been shown to express ES cell markers not currently 
identifi ed in other adult MSCs; these markers include Oct-4, Nanog, SSEA-3, 
SSEA-4, TRA-1-60 and TRA-1-81 [ 24 ], and their presence may signify higher 
potency and enhanced stem cell activity for DSPCs compared to other adult tissue- 
derived stem cells. They can differentiate into dental structures, as well as smooth 
and skeletal muscles, neurons, cartilage and bone under defi ned  in vitro  culture 
conditions [ 15 ,  25 ], engraft to muscular dystrophic skeletal muscle and improve 
post-myocardial infarction cardiac function in animal models although without evi-
dence of engraftment [ 26 ,  27 ]. 
 Notably, recent reports further speculated that the DPSCs might have originated 
from a neuroectodermal lineage. Indeed, the dental pulp stem cells express neural 
markers, and they can differentiate into functionally active neurons [ 28 – 30 ] and, 
when stimulated, express neurogenic substance such as glutamate. Transplantation 
of human DPSCs into rat SCI model has shown marked recovery of hind limb loco-
motor functions via improved preservation of neuronal fi laments and myelin sheaths 
by inhibition of apoptosis, promotion of regeneration of transected axons through 
paracrine mechanisms and replacement of lost cells by differentiating into mature 
oligodendrocytes [ 31 ]. 
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8.2.3  MSCs of the Periodontal Ligament, Apical Papilla 
and Follicles 
 Periodontal tissue contains both hard and soft tissues. Periodontal tissue ligaments 
are and gingival tissues are derived neural crest mesenchyme reside in the dental 
follicles during tooth development. Similar to the dental pulp and BM MSCs, the 
periodontal ligament stem cells (PDLSCs) are also thought to be perivascular. 
Clonally selected Stro-1 and CD146 as markers have been isolated from extracted 
human third molars and shown to differentiate into collagen-producing fi brogenic 
and calcifi ed cementogenic cells  in vivo to repair attachment lost in the periodon-
tium in immunosuppressed rats, showing the capacity of these cells to form colla-
gen fi bres, similar to Sharpey’s fi bres, connected to the cementum-like tissue 
suggesting the potential to regenerate PDL attachment [ 32 ]. 
 Other studies, however, failed to reproduce the osteogenic potential of the 
PDLSCs. These variations in fi ndings may support the notion that PDLSCs are 
heterogeneous MSC population that may contain subpopulations that have propen-
sities for either collagen-producing fi brogenic subclones or cement/osteogenic cell 
types. PDLSC do not form dentin-pulp complexes and instead possess osteoblastic 
and cementoblastic lineages in order to regenerate periodontal tissue and maintain 
PDL integrity [ 33 ]. Currently, PDLSCs are not currently reported for use in non- 
dental diseases; it is not clear whether this is due to a higher  susceptibility of 
PDLSCs to periodontal disease states and age related changes. 
 CFU-F forming cells isolated from the dental apical follicle (DFS) and stem cells 
of apical papilla (SCAP) of the developing tooth display similar MSC characteris-
tics in vitro, however with perhaps superior differentiation capacity of early/pro-
genitor cells compared to other MSCs from PDL and BM. These cells rapidly attach 
to the culture dishes, proliferate at a higher rate than other MSCs and express puta-
tive stem cell markers such as Notch-1 and nestin, as well as ES cell markers Oct-3/
Oct-4, Sox-2 and Nanog reported in SCAP [ 21 ,  33 ]. DFS and SCAP are shown to 
differentiate into dentine-like structures in  in vitro , functional hepatocyte-like cells 
and neuronal tissue structures (Table  8.1 ).
8.3  Muscle Stem Cells 
8.3.1  Potential of Orofacial Muscle Stem Cells in Cardiac 
Repair 
 Another intriguing potential source of stem cells may come from the progenitors of 
the orofacial muscle. The muscles of orofacial area including tongue, facial expres-
sion and mastication are classifi ed as skeletal myocytes. These muscles are vital for 
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mammalian survival dictated by their roles in the infant suckling and adult nutri-
tional intake. As well, recent studies have shown that these muscles possess devel-
opmental kinship to the cardiac muscle cells that are marked by similar gene 
expressions such as cardiac-specifi c transcription factors  Isl1  and  Nkx2-5 . The simi-
larities between these two groups also extend to the fatigue resistance of orofacial 
muscles [ 36 ], presumably due to similar glycolytic metabolic properties of the heart 
and presence of connexin molecules that are similar to cardiac confi gurations [ 37 ]. 
Unlike the cardiac muscles, the orofacial muscles have a remarkable ability to repair 
after injury, providing continuous myofi bril remodelling throughout life, suggesting 
an active and proliferative myogenic properties of the satellite cells in these mus-
cles. These attributes suggest that the orofacial muscle progenitors may emerge as 
an interesting and attractive source for regeneration of myocardium which only 
heals with non-contractile fi brosis after insults of MI. Thus far, limb muscle pro-
genitors which have been isolated to transplant into myocardium failed to couple 
with the endogenous cardiomyocytes resulting in arrhythmia [ 38 ]. This may be pre-
sumably due to the developmental origin and characteristics of the skeletal muscles 
of the trunk and limbs being distinct from those of the cardiac and facial muscle. 
Other cell types such as MSCs from the BM and endogenous cardiac source have 
produced less than optimal results in cardiac stem cell treatments [ 7 ,  39 ], with for-
mer resulting in short-term benefi ts due to trophic effect rather than new cardiomyo-
cyte generation [ 40 ] and the latter having limited therapeutic value as it is confi ned 
to neonates [ 41 ]. 
 Table 8.1  Orofacial MSC sources and their applications 
 Location  Differentiation potential 
 Applications for systemic 
diseases 
 Dental pulp stem cells 
(DPSCs) 
 Dentine  Cementum, PLD regeneration 
[ 32 ,  33 ] 
 Human exfoliated deciduous 
tooth (SHED) 
 Osteocytes  Bone generation [ 22 ] 
 Periodontal ligament stem 
cells (PDLS) 
 Cementum  Myocardial infarction [ 27 ] 
 Stem cells of apical papilla 
(SCAP) 
 Sharpey’s fi bres  Muscular dystrophy [ 26 ] 
 Cardiomyocytes  Limbal stem cell defi ciency 
[ 34 ] 
 Muscle cells  Hind limb ischemia [ 35 ] 
 Neurons  Rat spinal cord injury [ 31 ] 
 Hepatocytes 
 Corneal epithelium 
 Neurotrophic factor 
secretion 
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8.3.2  Developmental Similarities of Cardiac and Orofacial 
Myogenic Progenitors 
 Recent lineage tracing and clonal analysis have shown that the orofacial and the 
heart myocytes originate from the multipotent pharyngeal mesoderm cells which 
ingress through the streak at the same stage [ 42 ,  43 ] and share a distinct lineage 
kinship in development. Two myogenic linkages have been identifi ed [ 4 ]: (1) First, 
pharyngeal arch lineage gives rise to masticatory muscle and also contributes to 
myocardial cells in the right ventricle. (2) Second, pharyngeal arch lineage gives 
rise to muscles of facial expression and contributes myocardial cells to the arterial 
pole of the heart. 
 A key gene in early pharyngeal mesoderm genetic programme encodes the LIM 
homeodomain transcription factor  Islet1 ( Isl1 ) which has been shown to identify the 
multipotent cardiac progenitor cells in the early embryo and the differentiating ES 
cells that can give rise to myocardial, endothelial and smooth muscle descendants. 
This gene is also expressed in pharyngeal myogenic progenitor cells and downregu-
lated on differentiation to either cardiac or skeletal muscle fates [ 41 ]. Tzahor  et al . 
have shown that pharyngeal myogenic muscle progenitors apparently have exactly 
the same subset of craniofacial muscles originating from  Isl1 -expressing progenitor 
cells [ 42 ]. Others have found that treatment of brachiometric satellite cells activates 
cardiac gene expression including  Isl1 and  Tbx20 . This fi nding suggests that satel-
lite cells retain the environmental signals of their embryogenic progenitors, high-
lighting the potential use of these myoblasts for cardiac repair. Interestingly, while 
no equivalent population to satellite cells is found in cardiac muscle, a small number 
of residual ISl1-positive cells have been identifi ed and proposed to be resident pro-
genitor cells that may contribute to cardiac growth and repair in the foetal and early 
postnatal heart [ 44 ]. 
 Additionally in our laboratory, initial fi ndings of genetic lineage tracking and 
protein expression experiments using  Nkx2-5 , a cardinal cardiomyocyte marker, 
have shown remarkable similarity of the tongue and masticatory muscle throughout 
the embryonic development and in adults; as well, the adult tongue has a signifi cant 
pool of satellite that is marked by the cardiac transcription gene (data not shown), 
supporting the notion that the activation and cardiogenic differentiation are possible 
using these cells. 
8.3.3  An Interesting Example of Using Tongue Stem Cell 
for Cardiac Repair 
 Shibuya et al., in 2010, characterized for the fi rst time cardiomyocyte-like proper-
ties of cultured tongue muscle-derived stem cells. They showed that Sca-1-positive 
cells isolated from tongue muscles appear to differentiate into cardiomyocytes that 
electrically cooperate with adjacent cardiomyocytes. They presented the 
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cardiomyocyte phenotype with beating and Nkx2-5 expression. Interestingly, these 
cells preserve their expression of connexin43 and appear to form gap junctions, as 
indicated by the transfer of dye and synchronization of calcium transients among 
adjacent cells. Collectively, these fi ndings strongly suggest tongue progenitors may 
be ideal for cell therapy in heart disease [ 37 ]. Although their in vitro studies prove 
promising and their  in vivo fi ndings are limited, this may also be due to the markers 
that are used to isolate the progenitors which may not be targeted to the myogenic 
progenitors. 
 Myogenesis including cardiogenesis is complexly orchestrated. Understanding 
the developmental governance and the regulatory factors that determine the cell fate 
of the orofacial myocytes may shed light into both the function of the orofacial 
musculature and the cardiac repair mechanisms. 
8.4  Closing Remark 
 The interest in organ regeneration using stem cells has increased in the last decade. 
In this context, orofacial stem cells are promising candidates, as they are readily 
available and highly proliferative and possess multi-differentiation abilities. These 
cells not only provide therapeutic and tissue engineering cell source for orofacial 
area and dental regeneration but also provide additional source for systemic cells. 
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